Hikma Pharmaceuticals (HIK) Receives Add Rating from Peel Hunt

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “add” rating reissued by research analysts at Peel Hunt in a report released on Thursday.

Several other analysts have also issued reports on the company. Barclays reiterated an “underweight” rating on shares of Hikma Pharmaceuticals in a report on Monday, September 17th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a GBX 1,050 ($13.72) target price on shares of Hikma Pharmaceuticals in a report on Tuesday, August 21st. Citigroup upped their target price on Hikma Pharmaceuticals from GBX 2,100 ($27.44) to GBX 2,250 ($29.40) and gave the stock a “buy” rating in a report on Wednesday, October 3rd. Finally, Numis Securities reiterated a “hold” rating on shares of Hikma Pharmaceuticals in a report on Wednesday, August 15th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of GBX 1,346.89 ($17.60).

Shares of Hikma Pharmaceuticals stock opened at GBX 1,872 ($24.46) on Thursday. Hikma Pharmaceuticals has a one year low of GBX 814.20 ($10.64) and a one year high of GBX 2,346 ($30.65).

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.

Read More: How are Outstanding Shares Different from Authorized Shares?

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply